A Resource for Healthcare and Social Services Professionals
April 4, 2024
1:00 pm–2:00 pm ET
A drop-in session open to individuals working in the field of addiction. Includes discussion of an evidence-based article with implications for SUD practice. This month, lead author Marc LaRochelle, MD, MPH, will join us to discuss his article "Change in opioid and buprenorphine prescribers and prescriptions by specialty, 2016-2021," authored by LaRochelle MR, Jones CM, and Zhang K.
Via Zoom
Visit the meeting URL
Addiction Journal Club (AJC) is a monthly drop-in session where we meet to review an evidence-based article and discuss its implications for substance use disorder (SUD) practice. This includes new research and landmark studies relevant to SUD practice. AJC is distinct from other BMC Grayken Center for Addiction TTA events; it is designed to be less didactic and more of an interactive review of emerging data and trends related to caring for persons who use substances. It is also a great opportunity to network with addiction colleagues and share experiences about clinical practices.
This month, lead author Marc LaRochelle, MD, MPH, will join us to discuss his article "Change in opioid and buprenorphine prescribers and prescriptions by specialty, 2016-2021," authored by LaRochelle MR, Jones CM, and Zhang K. Click here to read the article.
Please register to attend this session via Zoom using the link at the top of this page.
Individuals working in the field of addiction medicine.
Boston Medical Center Grayken Center for Addiction, Bureau of Substance Addiction Services (BSAS/DPH), Opioid Response Network (ORN), Association for Multidisciplinary Education and Research in Substance use and Addiction (AMERSA)
Funding for this initiative was made possible (in part) by grant no. 1H79TI085588-02 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.